Clinical trialNCT03558503CompletedPhase 2Interventional

A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer

SponsorUroGen Pharma Ltd.Enrollment63Bladder CancerUrothelial CarcinomaUrothelial Carcinoma Bladder

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This Phase 2b, single-arm, multicenter study evaluated the efficacy and safety of UGN-102 as primary chemoablative therapy in patients with low grade intermediate risk non-muscle-invasive bladder cancer (LG IR NMIBC).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Elyse Seltzer, MD
UroGen Pharma
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

19 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Israel

Carmel Medical Center
Haifa, Israel
Rabin Medical Center
Petah Tikva, Israel

United States

Mayo Clinic Cancer Center
Phoenix, Arizona, United States
Arkansas Urology
Little Rock, Arkansas, United States
Loma Linda University
Loma Linda, California, United States
Providence Medical Institute
Santa Monica, California, United States
Clinical Research Center of Florida
Pompano Beach, Florida, United States
John Hopkins University
Baltimore, Maryland, United States
Adult & Pediatric Urology, Pc
Omaha, Nebraska, United States
Urology Las Vegas
Las Vegas, Nevada, United States
Manhattan Medical Research
New York, New York, United States
Montefiore Medical Center (albert Einstein)
New York, New York, United States
Weill Cornell Medical College
New York, New York, United States
Western New York Urology Associates
New York, New York, United States
the University of North Carolina
Chapel Hill, North Carolina, United States
Penn State Hershey State College
Hershey, Pennsylvania, United States
Carolina Urologic Research Center
Myrtle Beach, South Carolina, United States
Urology Associates, Pc
Nashville, Tennessee, United States
Urology San Antonio
Fredericksburg, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

UGN-102

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 15 Oct 2018
Primary completion: 3 Jan 2020
Completion: 21 Oct 2020
Last update posted: 16 Sept 2022
Registered enrollment: 63
Registry id: NCT03558503

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.